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Abstract
Background—Evidence-based guidelines recommend chemotherapy for medically fit patients
with stage II–IV non-small cell lung cancer (NSCLC). Adherence to chemotherapy guidelines has
rarely been studied among large populations, mainly because performance status (PS), a key
component in assessing chemotherapy appropriateness, is missing from claims-based datasets.
Among a large cohort of patients with known PS, we describe first line chemotherapy use relative
to guideline recommendations and identify patient factors associated with guideline concordant
use.
Patients and Methods—Insured patients, ages 50+, with stage II–IV NSCLC between 2000–
2007 were identified via tumor registry (n=406). Chart abstracted PS, automated medical claims,
Census tract information, and travel distance were linked to tumor registry data. Chemotherapy
was considered appropriate for patients with PS 0–2. Multivariate logit models were fit to evaluate
patient characteristics associated with chemotherapy over- and under-use per guideline
recommendations. Tests of statistical significance were two sided.
Results—Overall compliance with first line chemotherapy guidelines was 71%. Significant
(p<0.05) predictors of chemotherapy underuse (19%) included increasing age (odds ratio [OR],
1.09), higher income (OR, 1.02), diagnosed before 2003 (OR, 2.05), and vehicle access (OR, 6.96)
in the patient’s neighborhood. Significant predictors of chemotherapy overuse (10%) included
decreasing age (OR, 0.92), diagnosed after 2003 (OR, 3.24), and higher income (OR, 1.05) in the
patient’s neighborhood.
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Among NSCLC patients 29% do not receive guideline recommended chemotherapy treatment
missing opportunities for cure or beneficial palliation, or receiving chemotherapy with more risk
of harm than benefit. Care concordant with guidelines is influenced by age, economic
considerations such as income and transportation barriers.
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Introduction
Evidence-based treatment guidelines recommend the use of chemotherapy for medically fit
patients with unresectable or stage IV non-small cell lung cancer (NSCLC) to improve
survival, symptoms, and quality of life [1–4]. Although previous studies have documented
variability in the receipt of chemotherapy among patients with NSCLC [5–8] none of these
studies have included performance status (PS) [9], a key clinical component in assessing
chemotherapy appropriateness [3], because it is typically missing from claims-based
databases. The inability to study PS-appropriate chemotherapy use among large populations
of NSCLC patients has further precluded an understanding of the patient and other factors
that place patients with NSCLC at risk of chemotherapy use that is inconsistent with existing
guideline recommendations.
Determining whether care meets professional standards is important in lung cancer care.
Adherence to evidence-based guidelines has been used to assess the quality of health care
for a wide range of conditions [10], so it is natural to ask how often lung cancer care agrees
with guideline recommended care. Previous studies suggest that chemotherapy is sometimes
overused at the end of life, with 20% [11] to 43% [12] or more of lung cancer patients
receiving chemotherapy within just a few weeks of a patient’s death. Yet, lung cancer
patients who use hospice for at least one day – thus avoiding chemotherapy during their stay
in hospice, and getting appropriate symptom management – appear to live significantly
longer than lung cancer patients who never use hospice [13]. At the same time, an underuse
of curative surgery, combined chemotherapy and radiation [5, 6] and palliative
chemotherapy may unnecessarily increase the symptom burden and the death rate from this
disease.
The issue of guideline adherence has been more comprehensively examined in breast cancer
research where a number of studies have demonstrated improvement in survival when
patients were treated according to clinical practice guidelines [14–17]. Several breast cancer
studies have found that increased age, comorbidity, black race, lower educational
attainment, and advanced disease stage are associated with receipt of nonstandard treatment
regimens (including underuse), which in turn contributes to less favorable outcomes [18–
22]. Furthermore, a conceptual model that explains the underuse of effective therapy in
breast cancer has been proposed, where therapy underuse is explained by the interaction of
patient, physician, and system factors, each of which exists within a health care system and
an individual’s community [23] and is potentially fixable.
The purpose of this research is to use medical-record documented PS to quantify the extent
of adherence to evidence-based guidelines for use of chemotherapy among an insured
population diagnosed with NSCLC between 2000 and 2007, and to evaluate the patient and
other factors associated with both the under- and over-use of chemotherapy within this
cohort. By combining data from medical records with those available via an automated
tumor registry, medical claims, and Census data, we are able to consider the patients’
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clinical and socio-demographic characteristics, as well as characteristics of the
neighborhood in which they reside.
Methods
Study Population and Setting
Study patients were those receiving care from a 900-physician member, multispecialty,
salaried medical group practice in southeast Michigan. Data available from the medical
group’s tumor registry were used to identify all patients aged ≥ 50 years who were
diagnosed with NSCLC between January 1, 2000 and December 31, 2007. The medical
group, which provides care under both fee-for-service and capitated arrangements, staffs 27
primary care clinics throughout Detroit and the surrounding metropolitan area. Patients
eligible for study inclusion were those continuously enrolled in an affiliated health plan (i.e.,
health maintenance organization) for the 1-year period preceding their date of lung cancer
diagnosis. Patients for whom no stage of disease was available or for whom the stage at
diagnosis was 0 or I were excluded. The latter were excluded because chemotherapy was not
indicated for patients with stage 0 or I disease during this time period [24]. We also
excluded patients who died within one month of their diagnosis. None of the patients
included in the study sample received targeted therapies in lieu of chemotherapy as Gefitinib
and Erlotinib were neither approved for used as first line chemotherapy. The medical
group’s Institutional Review Board approved all aspects of the study protocol.
Primary Outcome of Interest
Instances in which patients with good PS did not receive first line chemotherapy were
classified as “underuse,” while instances in which patients with poor PS received
chemotherapy were classified as “overuse.” We have listed the relevant ASCO lung cancer
guidelines in Table 1, which shows the relative consistency. Per the American Society of
Clinical Oncology (ASCO) clinical practice guidelines issued in 2009 [25], chemotherapy
was recommended for patients with good PS (i.e., PS= 0–2) and not recommended for
patients with poor PS (i.e., PS=3–4). Earlier 1997 ASCO guidelines had recommended
chemotherapy for patients with PS=0–1 only [1]. The 2003 ASCO guideline recommended
combination chemotherapy for patients with PS=0–1, and single agent chemotherapy for
patients with PS=2, but no chemotherapy for patients with PS=3–4 [4]. Our baseline models
included patients with PS=0–2 in the good PS group. Alternative models that considered
PS=2 patients with the poor PS group were also evaluated. Two trained chart abstractors
reviewed inpatient and outpatient nursing and physician notes available within the patient’s
electronic medical record from 2 months before diagnosis until the first notation of death,
disenrollment, initiation of chemotherapy, or 6 months after diagnosis to obtain PS.
Abstractors recorded the PS documented closest to the diagnosis date, since most NSCLC
patients start treatment at the time of symptomatic diagnosis and watchful waiting is not
recommended by any guideline. If no specific PS was documented, they estimated PS based
on medical notes. In the latter case, notes regarding the patient’s functionality (e.g.,
references to shortness of breath, use of a wheelchair or other personal mobility devices,
labor force participation, exercising habits, activities of daily living, or other references to
mobility) were recorded and used to estimate PS. Inter-rater reliability between the 2
abstractors was assessed on a random subset of 40 observations and the resulting Cohen κ
was 0.88. Further details regarding abstraction of PS are provided elsewhere [26].
Automated Tumor Registry and Claims Data
Automated tumor registry and claims data were accessed to obtain patient demographic
characteristics, date of cancer diagnosis, stage at diagnosis, and comorbidities in the 12-
month period preceding diagnosis for each patient. Patient demographics included age,
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gender, and race. The age of the patient (in years) was recorded as of the date of lung cancer
diagnosis. Clinical measures for each patient included stage of disease at the time of
diagnosis and the Charlson comorbidity index [27]. Cancer stage was reported using the
American Joint Committee on Cancer (AJCC) stages II through IV. The Deyo adaptation of
the Charlson comorbidity index and each of its component diagnostic subgroups were
constructed using inpatient and outpatient diagnostic information available in the 12-month
period preceding diagnosis [28].
Socioeconomic Data
Socioeconomic information, including education level, median household income, and
vehicles per household were obtained from the 2000 US Census. Using patients’ residential
street address, Census tract level data were used to characterize the socioeconomic profile of
each patient’s neighborhood of residence. We also used MapPoint (2010; Microsoft
Corporation, Redmond, WA) to calculate the travel distance between each patient’s home
and the nearest chemotherapy facility that was affiliated with the group practice.
Statistical Analysis
We assigned patients into 4 distinct groups: patients with good PS (0–2, as baseline) who
received chemotherapy; patients with good PS who did not receive chemotherapy; patients
with poor PS who received chemotherapy; and patients with poor PS who did not receive
chemotherapy. Systematic unadjusted differences between patients receiving first line
chemotherapy and those who did not receive chemotherapy, within the good PS and poor PS
groups (patients in the first two groups and patients in the latter two groups) were examined,
using 2-sample Student t tests (or Wilcoxon rank sum tests) and chi-square tests, depending
on the nature of the characteristic. Two multivariate logistic regression models were fit to
evaluate the factors associated with receipt of first line chemotherapy, given the patient’s
PS. The first model estimated chemotherapy receipt among patients with good PS (i.e.,
evaluated factors associated with chemotherapy under use) while the second model
estimated chemotherapy receipt among patients with poor PS (i.e. evaluated factors
associated with chemotherapy overuse). In both models, we controlled for patient age at
diagnosis, gender, race, and comorbidities as well as the college graduation rate, median
household income, and vehicle access in their neighborhood, distance to nearest
chemotherapy facility, and year of diagnosis.
We used SAS statistical software (version 9.1.3; SAS Institute Inc, Cary, NC) for all
analyses, and considered p < .05 to be statistically significant. All tests for statistical
significance were two sided.
Results
Cohort Characteristics
A total of 1,099 NSCLC patients were originally considered for the study, but only 406 met
the criteria for study eligibility; we excluded 385 patients whose AJCC stage was either 0, 1,
or unknown, 162 patients who did not meet the minimum enrollment criteria, 110 patients
whose PS was unknown because it was not documented in the chart, and 36 patients who
died within one month of diagnosis. Overall sample characteristics are reported in Table 2.
The mean age of the cohort was 67.4 years (standard deviation [SD], 8.9 years). Just under
half (41%) were female, whereas the racial distribution was 69% white, 29% black, and 2%
of other races. The AJCC staging distribution was as follows: 11% of patients were
diagnosed with stage II disease, 41% were diagnosed with stage IIII disease, and 48% were
diagnosed with stage IV disease. The average Charlson comorbidity index across the sample
was 1.3 (SD, 1.6).
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At the Census tract level, the mean college graduation rate for the cohort was 6.9% (SD,
5.6), the median household income (in 2000) was $49,200 (SD, 21,900), and 12.2% (SD,
19.0) of residents lived in households that had no vehicles. The average travel distance of
patients to the nearest chemotherapy facility was 10.8 miles (SD, 11.7).
Across the sample, 13% of patients received no anti-cancer treatment for their lung cancer,
1% received surgery only, 16% received radiation therapy only, 13% received chemotherapy
only, 5% received a combination of surgery and chemotherapy but no radiation, 44%
received radiation and chemotherapy but no surgery, and 8% received all three modes of
treatment.
Chemotherapy Receipt by Performance Status
Table 3 reports receipt of first line chemotherapy by stage and PS. Overall, 77 patients
(19%) with good PS (0–2) did not receive chemotherapy, while 39 patients (10%) with poor
PS received chemotherapy. Among patients diagnosed with stage II disease, 9 (20%) with
good PS did not receive chemotherapy and 6 (14%) with poor PS received it. Among those
diagnosed with stage III disease, 31 (19%) with good PS did not receive chemotherapy and
9 (5%) with poor PS received it. Among those diagnosed with stage IV disease, 37 (19%)
with good PS did not receive chemotherapy and 24 (12%) with poor PS received it.
Table 4 reports the unadjusted differences in cohort characteristics between patients
receiving first line chemotherapy and those not receiving it, across 2 groups: patients with
good PS and poor PS. Among patients with good PS, there were significant differences
between those receiving chemotherapy and those not receiving it by age at diagnosis, the
patient’s Charlson comorbidity index, and the vehicle ownership rate in the patient’s
neighborhood. Among patients with poor PS, there were significant differences between
those receiving chemotherapy and those not receiving it by age and median household
income in the patient’s neighborhood.
Factors Associated with the Non-Receipt of Chemotherapy among Patients with Good
Performance Status
Results from the multivariable logistic regression model for factors associated with the non-
receipt of chemotherapy among patients with good PS are presented in Table 5. As indicated
in the model, patients who are significantly less likely to receive chemotherapy when the PS
is good include older patients, patients residing in neighborhoods with higher median
household income, and those living in neighborhoods with a higher percentage of
households without any vehicle. At the same time, patients who are more likely to receive
chemotherapy when their PS is good include patients residing in neighborhoods with a
higher percentage of college graduates and patients diagnosed in 2003 or later. Factors that
were not significant in this model included gender, race, comorbidities, and distance to
nearest chemotherapy facility. Results from models in which patients with PS=2 (n=44)
were aligned with the poor PS group (as opposed to the good PS group) were neither
statistically nor substantively different (data not shown).
Factors Associated with the Receipt of Chemotherapy among Patients with Poor
Performance Status
Table 6 reports the results of the logistic regression model for chemotherapy receipt among
patients with poor PS. Factors that were associated with significantly higher odds of
chemotherapy receipt when PS is poor include median household income and being
diagnosed in 2003 or later. Older patients and those who lived in neighborhoods with a
higher percentage of college graduates are less likely to receive chemotherapy when they
have poor PS. Factors that were not significant in this model included gender, race,
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comorbidities, vehicle access, and distance to nearest chemotherapy facility. Results from
models in which patients with PS=2 (n=44) were aligned with the poor PS group were
neither statistically nor substantively different (data not shown).
Discussion
Performance status is widely recognized as a predictor for treatment appropriateness and
reducing chemotherapy to patients with poor PS has been recommended as one way to
increase health care quality and reduce costs [29]. Using the first large cohort of patients
with lung cancer for whom PS is known, we found the overall adherence to evidence-based
guidelines for chemotherapy treatment to be 71%. Among those whose care was non-
concordant with guideline recommendations, 19% did not receive chemotherapy when it
was indicated and 10% received chemotherapy when it was not recommended. We recorded
a higher adherence rate than previous lung cancer studies that used population-based
Medicare data and did not control for PS [5–8]. We find that older patients are less likely to
use chemotherapy, regardless of their PS. That is, among patients with good PS, older
patients are less likely to receive recommended chemotherapy, and among patients with
poor PS, they are also less likely to receive chemotherapy. While the latter likely implies
high quality care, the former does not since elderly patients derive benefit too [25].
Variations in the receipt of chemotherapy by age are consistent with findings from previous
studies [5–8]. Whether this is a result of patient preferences or barriers, physician bias, or a
combination of these is not known.
The higher the median household income in the patient’s neighborhood of residence the
more likely they are to be out of compliance in both directions, both “overusing” and
“underusing” chemotherapy. As with our findings of differences in chemotherapy use by
patient age, we are not able to determine the extent to which observed utilization is a result
of patient preferences or barriers, physician bias or a combination of these.
Unlike other studies that analyzed Medicare claims data, we considered a rarely studied
managed care cohort that included younger patients as well as older ones, although our
median age of 67 was close to the US median age at diagnosis of 71 [30]. Another notable
difference of this study is that we found no racial differences in the receipt of chemotherapy
(either underuse or overuse). This difference may be attributable to two factors. First, our
study population consisted of patients who received their care through a managed care plan,
whereas previous studies have focused mainly on seniors with traditional Medicare (i.e.,
Parts A and B), not enrolled in a Medicare managed care plan (i.e., Part C). Research
suggests that managed care plans reduce health care disparities, at least for some broadly
defined measures of access to care [31]. Second, unlike prior studies [5, 6, 8], we were able
to control for PS as well as several socioeconomic characteristics at the census tract level,
i.e., education, income, and car ownership. It may not be race, per se, that leads to
previously documented treatment disparities, but rather PS and socioeconomic
characteristics (both of which are highly correlated with race), that underlies observed
chemotherapy treatment patterns.
Finally, among the urban/suburban population studied here, we did not find travel distance
to be associated with recommended chemotherapy treatment. Instead, we found that if fewer
households in a patient’s neighborhood had access to a car, this travel barrier was associated
with underuse of chemotherapy relative to guideline recommendations. This finding implies
that even among a non-rural population, the presence of transportation barriers is an
important predictor of the underuse of chemotherapy among patients with good PS. Thus,
despite the health system in which this study was conducted having multiple and
geographically dispersed clinics that offer chemotherapy treatment, our findings suggest that
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patients without access to a car may have difficulty reaching a clinic, even when there is a
clinic a relatively short distance from their home. This suggests a helpful question to ask on
intake screening: “Will you have difficulty getting to your next appointment?”
The results of the current study should be interpreted in light of the following limitations.
First, these findings are based on a cohort of insured cancer patients, and adherence rates as
well as the factors associated with them may differ among an uninsured population.
Similarly, models were developed on a sample of patients receiving their care from one
delivery system located in a large urban area. Therefore, care should be taken when
generalizing findings to other delivery settings and locales. Likewise, models may exclude
important factors associated with chemotherapy receipt including provider characteristics
and variations across health systems and geographical regions. However, the average age
and other characteristics of our cohort are similar to the whole U.S. Finally, this study was
not intended to assess appropriateness of specific chemotherapy regimens and further it is
not known whether chemotherapy was given with good intent for palliative reasons in lieu
of hospice to those with poor PS, and if there was any subsequent impact on symptom
burden or hospitalizations for side effects.
In summary, about 71% of patients in an insured population received chemotherapy
concordant with guideline recommendations based on performance status, but 29% did not.
There will be over 222,000 people diagnosed in the U.S. with lung cancer in 2011 [32].
Given the effectiveness of modern chemotherapy for palliation and prolonged survival, 19%
of patients almost certainly did not live as long or as well as they might have with
chemotherapy, and about 10% of patients received chemotherapy that had little chance of
benefit and excess risk of toxicity including hospitalizations, excess cost, and delay of entry
into hospice.
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Table 1
ASCO Recommendations for Chemotherapy by Eastern Cooperative Oncology Group (ECOG) Performance
Status (PS) and Year
ECOG PS
Year 0–1 2 3–4
1997[1] Chemotherapy appropriate Chemotherapy possibly appropriate Not appropriate due to toxicity
and lack of response
2003[2] Combination chemotherapy recommended No change; chemotherapy possibly appropriate. If
chemotherapy is given, single agent chemotherapy
recommended
Not recommended due to
toxicity and lack of response
2009[3] No change No change
[1]
Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of
Clinical Oncology. J Clin Oncol 1997;15:2996–3018.
[2]
Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR. American
Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330–53.
[3]
Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi
S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G. American Society of Clinical Oncology Clinical Practice Guideline update on
chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251–66.
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Table 2
Overall Sample Characteristics, Lung Cancer Patients, Stages II–IV (n = 406)
Demographic Characteristics
 Average age at diagnosis (SD) 67.4 (8.9)
 Gender (%)
  Female 41
  Male 59
 Race (%)
  Black 29
  White 69
  Other 2
Clinical Characteristics
 AJCC stage (%)
  II 11
  III 41
  IV 48
 Average Charlson comorbidity index (SD) 1.3 (1.6)
Socioeconomic Characteristics
 Pct with college degree (SD) 6.9 (5.6)
 Median household income in $1000s (SD) 49.2 (21.9)
Access to Treatment
 Pct without vehicle (SD) 12.2 (19.0)
 Distance (miles) to chemotherapy facility (SD) 10.8 (11.7)
Treatment(s) Received
 No treatment (%) 13
 Surgery only (%) 1
 Radiation therapy only (%) 16
 Chemotherapy only (%) 13
 Surgery + radiation therapy (%) 0
 Surgery + chemotherapy (%) 5
 Radiation + chemotherapy (%) 44
 Surgery + radiation + chemotherapy (%) 8
SD: Standard deviation
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Table 3
Chemotherapy Receipt by Performance Status (PS), (N = 406)
Chemotherapy Received?
Yes No
All Cases, (N = 406)
ECOG PS
0–1 213 (52%) 63 (16%)
2 30 (7%) 14 (3%)
3–4 39 (10%) 47 (12%)
Stage II, (N = 44)
ECOG PS
0–1 25 (57%) 9 (20%)
2 1 (2%) 0 (0%)
3–4 6 (14%) 3 (7%)
Stage III, (N = 165)
ECOG PS
0–1 99 (60%) 25 (15%)
2 8 (5%) 6 (4%)
3–4 9 (5%) 18 (11%)
Stage IV, (N = 197)
ECOG PS
0–1 89 (45%) 29 (15%)
2 21 (11%) 8 (4%)
3–4 24 (12%) 26 (13%)
ECOG: Eastern Cooperative Oncology Group
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Table 4
Sample Characteristics, by Performance Status (PS) and Choice of Chemotherapy Receipt or Non-Receipt, for
Lung Cancer Stages II–IV (n = 406)
Good PS (n = 320) Poor PS (n = 86)
Chemo (n = 243) No Chemo (n = 77) Chemo (n = 39) No Chemo (n = 47)
Demographic Characteristics
 Average age at diagnosis (SD) 65.5 (8.5)a 71.4 (8.9)a 66.9 (9.0)b 71.1 (7.5)b
 Gender (%)
  Female 41 47 36 36
  Male 59 53 64 64
 Race (%)
  Black 26 30 31 36
  White 72 66 69 58
  Other 2 4 0 6
Clinical Characteristics
 AJCC stage (%)
  II 11 12 15 6
  III 44 42 23 39
  IV 45 48 62 55
 Average Charlson comorbidity index (SD) 1.0 (1.4)a 1.4 (1.5)a 1.9 (2.0) 2.3 (2.3)
Socioeconomic Characteristics
 Pct with college degree (SD) 7.1 (6.0) 6.1 (4.9) 6.7 (5.9) 6.9 (4.4)
 Median household income in $1000s (SD) 50.4 (22.2) 47.6 (19.8) 52.4 (27.8)b 42.7 (16.6)b
Access to Treatment
 Pct without vehicle (SD) 10.0 (15.1)a 15.9 (21.8)a 12.8 (17.7) 16.3 (29.3)
 Distance (miles) to chemotherapy facility (SD) 11.3 (13.6) 10.6 (8.7) 9.5 (8.0) 9.6 (6.4)
Treatment(s) Received
 No treatment (%) - 42 - 45
 Surgery only (%) - 5 - 2
 Radiation therapy only (%) - 52 - 53
 Chemotherapy only (%) 17 - 31 -
 Surgery + radiation therapy (%) - 1 - -
 Surgery + chemotherapy (%) 8 - - -
 Radiation + chemotherapy (%) 62 - 64 -
 Surgery + radiation + chemotherapy (%) 13 - 5 -
Good PS: ECOG 0–2, Poor PS: ECOG>2
SD: Standard deviation
a
Among patients with good PS, significant difference by chemotherapy receipt/non-receipt, at 5% level
b
Among patients with poor PS, significant difference by chemotherapy receipt/non-receipt, at 5% level
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Table 5
Factors Associated with Non-Receipt of Chemotherapy among Patients with Good Performance Status (PS),
for Lung Cancer Stages II–IV (N = 320)
Performance Status = Good Odds of Under Use (95% CI) P Value
Patient Demographics
 Age at diagnosis (years) 1.09 (1.05–1.13) <0.01
 Gender = female 1.35 (0.77–2.37) 0.29
 Race = white 0.75 (0.36–1.58) 0.46
Clinical Characteristics
 Charlson comorbidity index 1.16 (0.96–1.39) 0.13
Socioeconomic Characteristics
 College degree 0.93 (0.86–1.00) 0.07
 Median income ($1000s) 1.02 (1.00–1.04) 0.05
Access to Treatment
 Pct without vehicle 6.96 (1.00–49.34) 0.05
 Distance to chemo facility 1.00 (0.99–1.03) 0.50
Guidelines




Good PS: ECOG 0–2
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Table 6
Factors Associated with Receipt of Chemotherapy among Patients with Poor Performance Status (PS), for
Lung Cancer Stages II–IV (N = 86)
Performance Status = Poor Odds of Over Use (95% CI) P Value
Patient Demographics
 Age at diagnosis (years) 0.92 (0.86–0.98) 0.01
 Gender = female 0.87 (0.32–2.38) 0.79
 Race = white 0.83 (0.24–2.85) 0.77
Clinical Characteristics
 Charlson comorbidity index 1.01 (0.78–1.32) 0.92
Socioeconomic Characteristics
 College degree 0.89 (0.78–1.02) 0.08
 Median income ($1000s) 1.05 (1.01–1.10) 0.02
Access to Treatment
 Pct without vehicle 3.41 (0.25–46.81) 0.36
 Distance to chemo facility 0.97 (0.90–1.04) 0.38
Guidelines
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